Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX in Locally Advanced or Metastatic Gastric Cancer
NCT00354224Phase 2Terminated
- Sponsor
- Medical University of South Carolina
- Start
- Jan 2005
- Primary completion
- Aug 2008
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and oxaliplatin in gastric cancer (GC), sponsored by Medical University of South Carolina. Primary endpoint: Response Rate as Determined by RECIST. Started Jan 2005; status: terminated.
02
Drugs
capecitabineoxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00354224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354224.